ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,219.03
-0.05%
US Tech 100
17,741.60
0.10%
Dow Jones
39,383.30
-0.12%
Brent Oil
82.105
-1.33%
Bitcoin
61,370.57
-2.44%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Fusion Pharmaceuticals Inc (FUSN) Quote

Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc (FUSN)

NASDAQ
21.435
0.005
( 0.02% )
Updated: 12:53:02
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
21.435
Bid
21.43
Ask
21.44
Volume
143,365
21.42 Day's Range 21.45
2.31 52 Week Range 21.58
Market Cap
1.478B
Previous Close
21.43
Open
21.45
Last Trade
70
@
21.435
Last Trade Time
12:56:23
Financial Volume
$ 3,073,360
VWAP
21.4373
Average Volume (3m)
2,028,505
Shares Outstanding
68,990,263
Dividend Yield
-
PE Ratio
-15.58
Earnings Per Share (EPS)
-1.38
Revenue
2.07M
Net Profit
-94.9M

About Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monother... Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firm's lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.fusionpharma.com
Headquarters
Hamilton, Ontario, Can
Founded
1970
Fusion Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FUSN. The last closing price for Fusion Pharmaceuticals was $21.43. Over the last year, Fusion Pharmaceuticals shares have traded in a share price range of $ 2.31 to $ 21.58.

Fusion Pharmaceuticals currently has 68,990,263 shares outstanding. The market capitalization of Fusion Pharmaceuticals is $1.48 billion. Fusion Pharmaceuticals has a price to earnings ratio (PE ratio) of -15.58.

FUSN Latest News

More News

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

May 10 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 10 2024
Edgar (US Regulatory)

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer PR Newswire HAMILTON, ON...

May 09 2024
PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

May 07 2024
Edgar (US Regulatory)

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates

Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates Canada NewsWire HAMILTON, ON and BOSTON, May 7, 2024 Presented interim data from TATCIST...

May 07 2024
PR Newswire (Canada)

Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm

Kuehn Law Encourages HCP, IP, SLCA, and FUSN Investors to Contact Law Firm PR Newswire NEW YORK, April 26, 2024 NEW YORK, April 26, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation...

April 26 2024
PR Newswire (US)

Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order

Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order PR Newswire HAMILTON, ON and BOSTON, April 25, 2024 HAMILTON, ON and BOSTON, April...

April 25 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.015-0.069930069930121.4521.521.3541418521.41149041CS
40.1850.87058823529421.2521.5821.1848649421.38768133CS
129.34577.295285359812.0921.589.09202850519.4364883CS
2617.375427.9556650254.0621.583.84152037715.60136534CS
5216.785360.9677419354.6521.582.3180155914.86611884CS
15612.955152.7712264158.4821.581.9832909812.93312019CS
2602.93515.864864864918.521.581.9827341213.02274327CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FFIEFaraday Future Intelligent Electric Inc
$ 0.275
(350.82%)
921.81M
CTNTCheetah Net Supply Chain Service Inc
$ 3.871
(225.29%)
31.08M
CRKNCrown Electrokinetics Corporation
$ 0.0764
(66.81%)
99.94M
MTCMMTec Inc
$ 7.97
(64.33%)
1.72M
SPWRSunPower Corporation
$ 4.2499
(54.54%)
109.81M
AUGXAugmedix Inc
$ 1.16
(-50.43%)
9.97M
NOTVInotiv Inc
$ 2.17
(-47.96%)
3.15M
AKYAAkoya BioSciences Inc
$ 2.8101
(-31.79%)
1.66M
EASTEastside Distilling Inc
$ 1.07
(-28.19%)
168.23k
SHIMShimmick Corporation
$ 2.6959
(-25.94%)
147.72k
FFIEFaraday Future Intelligent Electric Inc
$ 0.275
(350.82%)
921.81M
PLUGPlug Power Inc
$ 3.5502
(22.84%)
163.17M
SPWRSunPower Corporation
$ 4.2499
(54.54%)
109.81M
FCELFuelCell Energy Inc
$ 0.9396
(31.74%)
102.75M
CRKNCrown Electrokinetics Corporation
$ 0.0764
(66.81%)
99.94M

FUSN Discussion

View Posts
Monksdream Monksdream 1 month ago
FUSN over $20
👍️0
Monksdream Monksdream 2 months ago
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
March 19 2024 - 03:00AM
PR Newswire (US)
Alert
Print
Share On Facebook
Transaction includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities

Fusion shareholders to receive $21.00 per share in cash at closing plus a non-transferrable contingent value right (CVR) of $3.00 per share, representing a total transaction value of approximately $2.4 billion including the CVR

HAMILTON, ON and BOSTON, March 19, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Company has entered into a definitive agreement to be acquired by AstraZeneca. The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
👍️0
Monksdream Monksdream 4 months ago
FUSN new 52 week high
👍️0

Your Recent History

NASDAQ
FUSN
Fusion Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved